J
Julien Taieb
Researcher at University of Paris
Publications - 482
Citations - 11958
Julien Taieb is an academic researcher from University of Paris. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 50, co-authored 409 publications receiving 8679 citations. Previous affiliations of Julien Taieb include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.
Isabelle Trouilloud,Anne Claire Dupont-Gossard,Pascal Artru,Thierry Lecomte,Mélanie Gauthier,Thomas Aparicio,Anne Thirot-Bidault,David Malka,Céline Lobry,Amani Asnacios,Sophie Lacombe,Francine Fein,Daniela Fanica,Olivier Dubreuil,Lysiane Marthey,Aziz Zaanan,Franck Bonnetain,Julien Taieb +17 more
TL;DR: A new strategy to improve efficacy and tolerability of CPT-11 based regimen in MPA pts with histologically proven MPA was developed and the primary end point was rate of progression free survival at 6 months.
Journal ArticleDOI
Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.
TL;DR: It is shown how, with anti-HPV vaccines, immunity is a target in the prevention of SCCA and could in the future be used in its treatment.
Journal ArticleDOI
Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
Alexandre Ghazi,Delphine Le Corre,Camilla Pilati,Julien Taieb,Thomas Aparicio,Audrey Didelot,Shoukat Dedhar,Claire Mulot,Karine Le Malicot,Fatima Djouadi,Aurélien de Reyniès,Jean-Marie Launay,Jean-Marie Launay,Pierre Laurent-Puig,Sophie Mouillet-Richard +14 more
TL;DR: In this article, the integrin-linked kinase ILK was identified as a proximal effector of cellular prion protein PrPC that mediates its control on the colorectal cancer phenotype.
Journal ArticleDOI
Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.
Yung-Jue Bang,Lucjan Wyrwicz,Young Iee Park,Min-Hee Ryu,Alina Muntean,Carlos Gomez-Martin,Rosine Guimbaud,Fortunato Ciardiello,Narikazu Boku,Eric Van Cutsem,Julien Taieb,Huiling Xiong,Jenny Zhang,Jean-Marie Cuillerot,Jayne S. Gurtler +14 more
TL;DR: Avelumab* is a fully human anti-PD-L1 ligand that acts as a “spatially aggregating force” in the body to reprogram the immune response against multiple cancers.
Journal ArticleDOI
Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data.
Sandrine Boulet,Moreno Ursino,Peter F. Thall,Bruno Landi,Céline Lepère,Simon Pernot,Anita Burgun,Julien Taieb,Aziz Zaanan,Sarah Zohar,Anne-Sophie Jannot +10 more
TL;DR: A method that incorporates elicited expert weights associated with variables involved in dose reduction decisions into the Stochastic Search Variable Selection (SSVS), a Bayesian variable selection method, by using a power prior is proposed.